|Articles|June 1, 2016
Paperless Processes on the Way Out?
Author(s)Lisa Henderson
Survey reveals mixed adoption of paperless data collection in clinical trials, pointing to the need for greater alignment of new eClinical technologies and study conduct.
Advertisement
In January 2014, the FDA presented a webinar “Promoting eSource Data Capture,” to explain its Final Guidance on Electronic Source Data in Clinical Investigations. In a slide, the FDA said the worst case for source data capture is “transcription of data from paper or electronic sources to the eCRF (electronic case report form).” The reason being that there was no intervening paper step needed, less confusion on what is source and the decreased likelihood of data errors.
In April of this year, we conducted a survey with SCORR Marketing to evaluate the paperless trial. In this survey, of 143 respondents, 25% said 0%-10% of their data collection in clinical trials was paperless. The next highest was 22%, who said that greater than 75% of their trials were paperless. And 15% said between 51% and 75% were paperless. So the majority fall in the middle of paperless processes, leaving room for greater adoption in the coming years.
In fact, the majority of respondents-27%-said that in the next three years, 75% to 99% of the processes for clinical trials would be paperless. With the plethora of new technologies surrounding data aggregation, mining, and analytics in all critical areas of study conduct, we can only see that our respondents are correct in their view.
For more information, download SCORR’s free report here .
Articles in this issue
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- Q&A: Strategies for Successful Global Clinical Trial Delivery
September 12th 2025
- Vabysmo Shows Long-Term Efficacy and Safety in Wet AMD, PCV Patients
September 12th 2025
- Latest NIMBLE Study Results Highlight Progress in gMG Research
September 12th 2025
- ACT Brief Episode 8: Expert Insights on the Future of Obesity Drug Trials
September 11th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Phase III BRUIN CLL-313 Trial Finds Jaypirca Extends Progression-Free Survival in Treatment-Naïve CLL/SLL
2
Q&A: Strategies for Successful Global Clinical Trial Delivery
3
FDA Fast Tracks Sanofi’s Intravitreal Gene Therapy for Neovascular Age-Related Macular Degeneration
4
Latest NIMBLE Study Results Highlight Progress in gMG Research
5